Vitamin K2 (MK-7) in Focus: Research Gaps, Proven Benefits, and Formulation Strategy

Netherlands — 14 May 2026

For years, Vitamin D3 has been lauded as the panacea for bone health, its role in calcium absorption undisputed. Yet, a critical question remains: where does all that absorbed calcium go? Could an overemphasis on D3, without adequate consideration for its synergistic partner, Vitamin K2 (specifically MK-7), be inadvertently contributing to arterial calcification rather than preventing it? The evidence suggests a concerning oversight, particularly in the ubiquity of underdosed multivitamins.

What the Clinical Evidence Actually Shows

The established synergy between Vitamin D3 and K2 is often overlooked in mainstream supplementation. While D3 facilitates calcium absorption, K2 activates matrix Gla protein (MGP) and osteocalcin, crucial proteins that direct calcium to bones and teeth, simultaneously inhibiting its deposition in soft tissues like arteries. The Rotterdam Study, a landmark population-based cohort, reported in 2004 that high dietary intake of K2 (menaquinone) was associated with a significantly reduced risk of coronary heart disease and aortic calcification, particularly at intakes exceeding 32 µg/day. More recent intervention trials, such as the 3-year randomised, placebo-controlled study by Knapen et al. (2015), demonstrated that 180 µg/day of MK-7 effectively improved arterial stiffness and elasticity in postmenopausal women. However, it is crucial to note that many commercially available multivitamins provide a mere 20-45 µg of K2, a dose far below those shown to elicit significant cardiovascular or bone health benefits in clinical settings. "The industry has a habit of cherry-picking headline benefits without committing to the efficacious doses," states Dr. Eleanor Vance, a nutritional biochemist. "This leads to consumer disillusionment and undermines the ingredient's true potential." Funding for some of these studies has come from K2 ingredient suppliers, a point that requires careful consideration when evaluating the strength of the evidence.

The Formulation Reality

Formulating with Vitamin K2, particularly the menaquinone-7 (MK-7) form, presents several practical challenges. MK-7 is sensitive to light, heat, and certain excipients, notably mineral salts like calcium carbonate, which can degrade its stability. This necessitates careful selection of carriers and encapsulation technologies. Optimal forms include microencapsulated MK-7 or those suspended in oil matrices, which significantly improve shelf stability and bioavailability. The all-trans isomer of MK-7 is the biologically active form, and formulators must ensure their raw material suppliers guarantee a high percentage of this isomer. Co-formulation with D3 requires particular attention to prevent degradation; studies have shown that MK-7 can oxidise in the presence of D3 unless protected. This often translates to higher raw material costs and more complex manufacturing processes. "Achieving a stable, efficacious dose of MK-7 alongside D3 in a single capsule is not trivial," explains Mr. David Palmer, a senior formulation chemist. "It requires specialist knowledge and often, bespoke manufacturing solutions, which many multi-vitamin producers are unwilling to invest in given the tight margins."

Market Position and Commercial Viability

The global Vitamin K2 market is projected to reach approximately £350 million by 2028, exhibiting a compound annual growth rate of around 15%. This growth is driven by increasing consumer awareness of K2's benefits beyond bone health, particularly its cardiovascular implications. However, pricing pressures remain significant. While bulk MK-7 raw material costs have decreased, the need for specialised, stable forms can still make it a premium ingredient. For manufacturers, minimum order quantities (MOQs) for high-quality, stable MK-7 often start from 5-10 kg, representing a substantial inventory investment. Margins on K2-specific supplements are generally healthy, ranging from 40-60% at wholesale, but incorporating efficacious doses into cost-sensitive multivitamins can erode profitability. The challenge lies in justifying the increased unit cost to a market accustomed to cheaper, often underdosed, alternatives. Strategic positioning, emphasising the synergistic benefits with D3 and the cardiovascular protection, is crucial to command a premium.

What This Means for Netherlands

In the Netherlands, regulatory bodies like the NVWA (Netherlands Food and Consumer Product Safety Authority) align with EFSA guidelines regarding nutrient reference values. While a specific Reference Intake (RI) for K2 is not yet established, the demand for bone and cardiovascular health supplements is robust. Dutch consumers are generally well-informed and health-conscious, showing a growing interest in evidence-based nutrition. This presents a strong opportunity for brands willing to invest in properly dosed K2 products, particularly those explicitly highlighting the D3/K2 synergy. However, the competitive landscape is saturated with basic D3 and calcium supplements. Differentiation will hinge on clear communication of K2's unique benefits and the use of clinically relevant dosages, moving beyond the current trend of minimal inclusion in multis.

The Bottom Line for Formulators

Formulators should absolutely consider Vitamin K2 (MK-7) for future product development, particularly in conjunction with Vitamin D3. However, this is conditional on committing to clinically validated dosages, typically 90-180 µg/day, and investing in stable, high-quality raw materials. Underdosing K2 purely for label claim purposes risks undermining its efficacy and reputational damage. The commercial viability hinges on educating the market about its distinct, synergistic role, rather than treating it as a mere add-on. For those willing to navigate the formulation complexities and higher material costs, the potential for a differentiated, high-value product is significant.